BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 22425450)

  • 1. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease.
    Pereira CS; Azevedo O; Maia ML; Dias AF; Sa-Miranda C; Macedo MF
    Mol Genet Metab; 2013 Apr; 108(4):241-8. PubMed ID: 23433711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner.
    Pereira CS; Sa-Miranda C; De Libero G; Mori L; Macedo MF
    Eur J Immunol; 2016 Jan; 46(1):147-53. PubMed ID: 26426881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
    Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
    Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
    Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
    Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
    Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
    Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
    Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
    J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro model of Fabry disease.
    Shu L; Murphy HS; Cooling L; Shayman JA
    J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
    Ohashi T; Iizuka S; Ida H; Eto Y
    Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
    Choi JO; Lee MH; Park HY; Jung SC
    J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells.
    Porubsky S; Speak AO; Salio M; Jennemann R; Bonrouhi M; Zafarulla R; Singh Y; Dyson J; Luckow B; Lehuen A; Malle E; Müthing J; Platt FM; Cerundolo V; Gröne HJ
    J Immunol; 2012 Sep; 189(6):3007-17. PubMed ID: 22875802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
    Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.